Published in Eur J Cancer on May 31, 2012
18F-FLT (PET/CT) in Pediatrics With Myeloproliferative Neoplasms | NCT03121599
The correlation between apparent diffusion coefficient and tumor cellularity in patients: a meta-analysis. PLoS One (2013) 1.22
18F-FDG and 18F-FLT-PET imaging for monitoring everolimus effect on tumor-growth in neuroendocrine tumors: studies in human tumor xenografts in mice. PLoS One (2014) 1.04
Meta-analysis of the technical performance of an imaging procedure: guidelines and statistical methodology. Stat Methods Med Res (2014) 0.92
Repopulation of tumor cells during fractionated radiotherapy and detection methods (Review). Oncol Lett (2014) 0.90
Prognostic impact of [18F]fluorothymidine and [18F]fluoro-D-glucose baseline uptakes in patients with lung cancer treated first-line with erlotinib. PLoS One (2013) 0.90
Correlation between the Uptake of 18F-Fluorodeoxyglucose (18F-FDG) and the Expression of Proliferation-Associated Antigen Ki-67 in Cancer Patients: A Meta-Analysis. PLoS One (2015) 0.89
Evaluation of 3'-deoxy-3'-[18F]-fluorothymidine (18F-FLT) kinetics correlated with thymidine kinase-1 expression and cell proliferation in newly diagnosed gliomas. Eur J Nucl Med Mol Imaging (2012) 0.87
Diagnostic accuracy of (18)F amyloid PET tracers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging (2015) 0.86
PET in the management of locally advanced and metastatic NSCLC. Nat Rev Clin Oncol (2015) 0.84
FLT PET-CT in evaluation of treatment response. Indian J Nucl Med (2014) 0.84
A Phase II Study of 3'-Deoxy-3'-18F-Fluorothymidine PET in the Assessment of Early Response of Breast Cancer to Neoadjuvant Chemotherapy: Results from ACRIN 6688. J Nucl Med (2015) 0.84
Serum Vitamin D Level and Rheumatoid Arthritis Disease Activity: Review and Meta-Analysis. PLoS One (2016) 0.83
Monitoring of anti-cancer treatment with (18)F-FDG and (18)F-FLT PET: a comprehensive review of pre-clinical studies. Am J Nucl Med Mol Imaging (2015) 0.83
¹⁸F-FLT PET/CT as an imaging tool for early prediction of pathological response in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy: a pilot study. Eur J Nucl Med Mol Imaging (2015) 0.82
[18F]-fluorodeoxyglucose positron emission tomography can contribute to discriminate patients with poor prognosis in hormone receptor-positive breast cancer. PLoS One (2014) 0.82
Imaging Biomarkers in Immunotherapy. Biomark Cancer (2016) 0.81
The enhanced in vivo activity of the combination of a MEK and a PI3K inhibitor correlates with [18F]-FLT PET in human colorectal cancer xenograft tumour-bearing mice. PLoS One (2013) 0.81
Increased intratumoral fluorothymidine uptake levels following multikinase inhibitor sorafenib treatment in a human renal cell carcinoma xenograft model. Oncol Lett (2013) 0.81
Evaluation of FLT-PET-CT as an imaging biomarker of proliferation in primary breast cancer. Br J Cancer (2014) 0.81
[(18)F]-fluoro-L-thymidine PET and advanced MRI for preoperative grading of gliomas. Neuroimage Clin (2015) 0.81
Pharmacodynamic study of axitinib in patients with advanced malignancies assessed with (18)F-3'deoxy-3'fluoro-L-thymidine positron emission tomography/computed tomography. Cancer Chemother Pharmacol (2015) 0.80
PET/CT in Oncology: Current Status and Perspectives. Curr Radiol Rep (2013) 0.80
Correlations of (18)F-fluorothymidine uptake with pathological tumour size, Ki-67 and thymidine kinase 1 expressions in primary and metastatic lymph node colorectal cancer foci. Eur Radiol (2014) 0.78
Biomarkers in preclinical cancer imaging. Eur J Nucl Med Mol Imaging (2015) 0.78
Imaging Macrophage and Hematopoietic Progenitor Proliferation in Atherosclerosis. Circ Res (2015) 0.78
Correlation between apparent diffusion coefficient (ADC) and cellularity is different in several tumors: a meta-analysis. Oncotarget (2017) 0.78
Longitudinal noninvasive imaging of progesterone receptor as a predictive biomarker of tumor responsiveness to estrogen deprivation therapy. Clin Cancer Res (2014) 0.77
Applications of PET imaging with the proliferation marker [18F]-FLT. Q J Nucl Med Mol Imaging (2015) 0.77
(18)F-fluorothymidine PET imaging in gliomas: an update. Ann Nucl Med (2017) 0.77
Assessment of response to neoadjuvant radiochemotherapy with F-18 FLT and F-18 FDG PET/CT in patients with rectal cancer. Ann Nucl Med (2014) 0.76
Pharmacodynamic Biomarker Development for PI3K Pathway Therapeutics. Transl Oncogenomics (2016) 0.76
Thymidine phosphorylase influences [(18)F]fluorothymidine uptake in cancer cells and patients with non-small cell lung cancer. Eur J Nucl Med Mol Imaging (2014) 0.75
(18)F-FLT Positron Emission Tomography (PET) is a Pharmacodynamic Marker for EWS-FLI1 Activity and Ewing Sarcoma. Sci Rep (2016) 0.75
Evaluation of (18)F-fluorothymidine positron emission tomography ([(18)F]FLT-PET/CT) methodology in assessing early response to chemotherapy in patients with gastro-oesophageal cancer. EJNMMI Res (2016) 0.75
Preclinical Applications of 3'-Deoxy-3'-[(18)F]Fluorothymidine in Oncology - A Systematic Review. Theranostics (2017) 0.75
Effects of capecitabine treatment on the uptake of thymidine analogs using exploratory PET imaging agents: (18)F-FAU, (18)F-FMAU, and (18)F-FLT. Cancer Imaging (2016) 0.75
Proliferative and Glycolytic Assessment of the Whole-Body Bone Marrow Compartment. Mol Imaging Radionucl Ther (2015) 0.75
A comparison of FLT to FDG PET/CT in the early assessment of chemotherapy response in stages IB-IIIA resectable NSCLC. EJNMMI Res (2017) 0.75
In-vivo Comparison of (18)F-FLT uptake, CT Number, Tumor Volume in Evaluation of Repopulation during Radiotherapy for Lung cancer. Sci Rep (2017) 0.75
Proliferation PET image to characterize pathological spatial features in patients with non-small cell lung cancer: a pilot study. Int J Clin Exp Med (2015) 0.75
Comparison of Positron Emission Tomography Using 2-[18F]-fluoro-2-deoxy-D-glucose and 3-deoxy-3-[18F]-fluorothymidine in Lung Cancer Imaging. Chin Med J (Engl) (2016) 0.75
18 F-fluorothymidine uptake in follicular lymphoma and error-prone DNA repair. EJNMMI Res (2014) 0.75
FLT-PET for early response evaluation of colorectal cancer patients with liver metastases: a prospective study. EJNMMI Res (2017) 0.75
FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. Ann Oncol (2005) 2.65
Comparison of technetium-99m-HM-PAO leukocytes with indium-111-oxine leukocytes for localizing intraabdominal sepsis. J Nucl Med (1990) 2.63
Radiation dose rates from patients receiving iodine-131 therapy for carcinoma of the thyroid. Eur J Nucl Med (1996) 2.03
Simultaneous PET and MR imaging. Phys Med Biol (1997) 1.95
Radiation exposure of the families of outpatients treated with radioiodine (iodine-131) for hyperthyroidism. Eur J Nucl Med (1999) 1.95
A PET study of 18FDG uptake in soft tissue masses. Eur J Nucl Med (1999) 1.67
99Tcm sestamibi--a new agent for parathyroid imaging. Nucl Med Commun (1989) 1.63
Evaluation of (18)fluorodeoxyglucose positron emission tomography ((18)FDG PET) in the detection of malignant peripheral nerve sheath tumours arising from within plexiform neurofibromas in neurofibromatosis 1. J Neurol Neurosurg Psychiatry (2000) 1.62
Comparison of sestamibi, thallium, echocardiography and PET for the detection of hibernating myocardium. Eur J Nucl Med Mol Imaging (2003) 1.59
Which apparatus for inhaled pentamidine? A comparison of pulmonary deposition via eight nebulisers. Eur Respir J (1991) 1.54
The role of sentinel lymph node biopsy in patients with differentiated thyroid carcinoma. Eur J Surg Oncol (2006) 1.51
18F-FDG PET-CT uptake is a feature of both normal diameter and aneurysmal aortic wall and is not related to aneurysm size. Eur J Nucl Med Mol Imaging (2014) 1.47
DNA ploidy in proliferative verrucous leukoplakia. Oral Oncol (2006) 1.46
Detection of lymphoma in bone marrow by whole-body positron emission tomography. Blood (1998) 1.44
Gastric emptying in patients with chronic renal failure on continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant (1994) 1.40
Secretion of [123I] iodide in breast milk following administration of [123I] meta-iodobenzylguanidine. Eur J Nucl Med (1994) 1.39
Is perfusion lung scanning hazardous in pulmonary hypertension? Nucl Med Commun (1995) 1.38
Cerebral perfusion deficits in divers with neurological decompression illness. Nucl Med Commun (1993) 1.38
Being equipped for clinical PET. Lancet (2000) 1.35
18-FDG-PET as a prognostic indicator in the treatment of aggressive Non-Hodgkin's Lymphoma-comparison with CT. Leuk Lymphoma (2000) 1.34
Spindle cell lipoma of the oral cavity: report of a case. J Oral Pathol Med (1994) 1.32
Structure-function relationship of antibacterial synthetic peptides homologous to a helical surface region on human lactoferrin against Escherichia coli serotype O111. Infect Immun (1998) 1.30
MRI-based measurements of respiratory motion variability and assessment of imaging strategies for radiotherapy planning. Phys Med Biol (2006) 1.25
An improved analytical detector response function model for multilayer small-diameter PET scanners. Phys Med Biol (2003) 1.24
Evaluation of fluorine-18-fluorodeoxyglucose whole body positron emission tomography imaging in the staging of lung cancer. Ann Thorac Surg (1999) 1.24
Differential changes in brain glucose metabolism during hypoglycaemia accompany loss of hypoglycaemia awareness in men with type 1 diabetes mellitus. An [11C]-3-O-methyl-D-glucose PET study. Diabetologia (2005) 1.17
Fluorodeoxyglucose positron emission tomography in the evaluation of germ cell tumours at relapse. Br J Cancer (2000) 1.16
Radionuclide parathyroid imaging. J Nucl Med (1997) 1.15
Dual energy X-ray absorptiometry normal reference range use within the UK and the effect of different normal ranges on the assessment of bone density. Br J Radiol (1995) 1.13
Evaluation of fluorodeoxyglucose positron emission tomography in the management of soft-tissue sarcomas. J Bone Joint Surg Br (1998) 1.12
Optimization of noise-equivalent count rates in 3D PET. Phys Med Biol (1996) 1.09
Thoracic respiratory motion estimation from MRI using a statistical model and a 2-D image navigator. Med Image Anal (2011) 1.09
Elastase in gingival crevicular fluid from smokers and non-smokers with chronic inflammatory periodontal disease. Oral Dis (1995) 1.09
Establishment of a UK-wide network to facilitate the acquisition of quality assured FDG-PET data for clinical trials in lymphoma. Ann Oncol (2010) 1.08
ERBB receptors in developing, dysplastic and malignant oral epithelia. Oral Oncol (2007) 1.08
Letter to the editor re: positron emission tomography with [(18)F]-3'-deoxy-3'fluorothymidine (FLT) as a predictor of outcome in patients with locally advanced resectable rectal cancer: a pilot study. Mol Imaging Biol (2013) 1.07
The value of the chest radiograph in reporting aerosol ventilation-perfusion scans. Nucl Med Commun (1998) 1.07
Radiation dose rates post 131I therapy and advice to patients on discharge from hospital. Health Phys (1997) 1.07
Radiation dose rates from patients undergoing PET: implications for technologists and waiting areas. Eur J Nucl Med (2000) 1.07
Delivery of ultrasonic nebulized aerosols to a lung model during mechanical ventilation. Am Rev Respir Dis (1993) 1.06
(99m)Tc(V)DMSA quantitatively predicts (188)Re(V)DMSA distribution in patients with prostate cancer metastatic to bone. Eur J Nucl Med (2000) 1.06
Temozolomide in the management of dopamine agonist-resistant prolactinomas. Clin Endocrinol (Oxf) (2012) 1.05
A study of artefacts in simultaneous PET and MR imaging using a prototype MR compatible PET scanner. Phys Med Biol (1999) 1.04
Non-invasive assessment of skeletal kinetics using fluorine-18 fluoride positron emission tomography: evaluation of image and population-derived arterial input functions. Eur J Nucl Med (1999) 1.04
Changes in regional brain (18)F-fluorodeoxyglucose uptake at hypoglycemia in type 1 diabetic men associated with hypoglycemia unawareness and counter-regulatory failure. Diabetes (2001) 1.03
Human Gyrovirus Apoptin shows a similar subcellular distribution pattern and apoptosis induction as the chicken anaemia virus derived VP3/Apoptin. Cell Death Dis (2012) 1.03
18-FDG-PET for the assessment of residual masses on CT following treatment of lymphomas. Ann Oncol (2000) 1.02
Escalation and intensification of radiotherapy for stage III non-small cell lung cancer: opportunities for treatment improvement. Clin Oncol (R Coll Radiol) (2009) 1.02
Basal cell adenocarcinoma in minor salivary glands. Histopathology (2003) 1.01
FDG-PET as a "metabolic biopsy" tool in non-lung lesions with indeterminate biopsy. Eur J Nucl Med Mol Imaging (2002) 1.00
Randoms variance reduction in 3D PET. Phys Med Biol (1999) 1.00
Pulmonary deposition of nebulised amiloride in cystic fibrosis: comparison of two nebulisers. Thorax (1991) 0.99
The impact of PET scanning on management of paediatric oncology patients. Eur J Nucl Med Mol Imaging (2004) 0.99
Analysis and comparison of two methods for motion correction in PET imaging. Med Phys (2012) 0.98
PET and NMR dual acquisition (PANDA): applications to isolated, perfused rat hearts. NMR Biomed (1997) 0.98
A study of the effects of sumatriptan on myocardial perfusion in healthy female migraineurs using 13NH3 positron emission tomography. Neurology (1997) 0.98
Quantification of skeletal kinetic indices in Paget's disease using dynamic 18F-fluoride positron emission tomography. J Bone Miner Res (2002) 0.97
S100, alpha-smooth muscle actin and cytokeratin 19 immunohistochemistry in odontogenic and soft tissue myxomas. J Clin Pathol (1995) 0.96
Regional lung epithelial leakiness in smokers and nonsmokers. Nucl Med Commun (1985) 0.96
Quantitative assessment of apoptosis in oral lichen planus. Oral Surg Oral Med Oral Pathol Oral Radiol Endod (1999) 0.94
Fatal Stevens-Johnson syndrome in a patient on captopril and allopurinol. Lancet (1984) 0.94
Paediatric nutrition risk scores in clinical practice: children with inflammatory bowel disease. J Hum Nutr Diet (2012) 0.94
Expression of ICAM-1 and E-selectin in gingival tissues of smokers and non-smokers with periodontitis. J Oral Pathol Med (2002) 0.93
Valproate for the treatment of acute bipolar depression: systematic review and meta-analysis. J Affect Disord (2009) 0.93
Variability in the measurement of nebulized aerosol deposition in man. Clin Sci (Lond) (1991) 0.92
Pulmonary deposition of a nebulised aerosol during mechanical ventilation. Thorax (1993) 0.92
Recurrent Strongyloides stercoralis infection in a patient with T-cell lymphoma-leukaemia. Lancet (1984) 0.92
Non-invasive management of fever and breathlessness in HIV positive patients. Eur Respir J (1991) 0.91
Lung 99Tcm-DTPA transfer: a method for background correction. Nucl Med Commun (1985) 0.91
[(18)F]Fluorodeoxyglucose positron emission tomography and its prognostic value in lung cancer. Eur J Cardiothorac Surg (2000) 0.91
Gingival fibromatosis with prune-belly syndrome. Oral Surg Oral Med Oral Pathol Oral Radiol Endod (1998) 0.90
Effect of corrections for blood glucose and body size on [18F]FDG PET standardised uptake values in lung cancer. Eur J Nucl Med (2001) 0.90
Prognostic value of FDG PET imaging in malignant pleural mesothelioma. J Nucl Med (2000) 0.90
The value of positron emission tomography scanning in the detection of subclinical metastatic melanoma. J Am Acad Dermatol (2000) 0.89
Fluorodeoxyglucose PET in the initial staging of germ cell tumours. Eur J Nucl Med (2000) 0.89
Abnormal DNA content in oral epithelial dysplasia is associated with increased risk of progression to carcinoma. Br J Cancer (2010) 0.89
Potential mechanisms of susceptibility to periodontitis in tobacco smokers. J Periodontal Res (1999) 0.89
FDG-PET as a "metabolic biopsy" tool in thoracic lesions with indeterminate biopsy. Eur J Nucl Med (2001) 0.88
Differences in regional bone metabolism at the spine and hip: a quantitative study using (18)F-fluoride positron emission tomography. Osteoporos Int (2012) 0.88
2-Fluorine-18-fluoro-2-deoxy-D glucose positron emission tomography in the pretreatment staging of Hodgkin's disease: influence on patient management in a single institution. Ann Oncol (2000) 0.88
Fast generation of 4D PET-MR data from real dynamic MR acquisitions. Phys Med Biol (2011) 0.88
A helical region on human lactoferrin. Its role in antibacterial pathogenesis. Adv Exp Med Biol (1998) 0.88
Measurement of radiation dose to the thyroid using positron emission tomography. Br J Radiol (1987) 0.88
Prospective evaluation of soft tissue masses and sarcomas using fluorodeoxyglucose positron emission tomography. Br J Surg (1999) 0.87
Heterogeneity, histological features and DNA ploidy in oral carcinoma by image-based analysis. Oral Oncol (2005) 0.87
Grading oral epithelial dysplasia: analysis of individual features. J Oral Pathol Med (2011) 0.86
Ventilation perfusion imaging--again. Nucl Med Commun (1992) 0.86
Algorithms for calculating detector efficiency normalization coefficients for true coincidences in 3D PET. Phys Med Biol (1998) 0.86
Therapeutic implications of thymic uptake of radioiodine in thyroid carcinoma. Eur J Nucl Med (1998) 0.86
The challenges of integrating molecular imaging into the optimization of cancer therapy. Integr Biol (Camb) (2011) 0.85
Solid phase synthesis of [18F]labelled peptides for positron emission tomography. Bioorg Med Chem Lett (2000) 0.85
Folic acid absorption in patients infected with the human immunodeficiency virus. J Intern Med (1991) 0.85
Developments in component-based normalization for 3D PET. Phys Med Biol (1999) 0.85
Evaluation of myocardial perfusion using positron emission tomography in infants following a neonatal arterial switch operation. Pediatr Cardiol (2000) 0.84
Pyostomatitis vegetans associated with asymptomatic ulcerative colitis: a case report. Oral Surg Oral Med Oral Pathol Oral Radiol Endod (1999) 0.84